Results 111 to 120 of about 8,704 (178)

UNI-494 treatment improves measures of renal dysfunction and cardiac pathology in male rats receiving L-NAME and angiotensin II. [PDF]

Physiol Rep
Ho FJM, Siow CJR, Aljaibeji H, Ding M, Mitchell RN, Medicherla S, Reddy G, Gupta S, Williams GH, Romero JR.   +9 more
europepmc   +1 more source

Cardiovascular risk in primary aldosteronism: inflammatory drivers, residual risk, and emerging combination strategies. [PDF]

Front Endocrinol (Lausanne)
Liu H, Wu Z, Liu X, Hu Y, Zhang K, Shang J.   +5 more
europepmc   +1 more source

Kidney function trajectories before and after hospitalization for heart failure with reduced ejection fraction. [PDF]

Eur Heart J
Kobayashi M, Bayes-Genis A, Duarte K, McMurray JJV, Ferreira JP, Pocock SJ, Van Veldhuisen DJ, Lupón J, Pitt B, Zannad F, Girerd N.   +10 more
europepmc   +1 more source

Efficacy and safety of mineralocorticoid receptor antagonists in heart failure: a meta-analysis of randomized controlled trials. [PDF]

BMC Cardiovasc Disord
Wu J, Pei Y, Wu J, Huang Y.
europepmc   +1 more source

Diabetic kidney disease, biomarkers, and finerenone. [PDF]

Diabetes Obes Metab
Verma A, Upadhyay A.
europepmc   +1 more source

Correction: Adverse effects of finerenone in patients with heart failure: a systematic review and meta-analysis. [PDF]

Front Cardiovasc Med
Yu W, Luo F, Rao J, Lei G, Wu Q, Shen W, Yang P, Li P.   +7 more
europepmc   +1 more source

Influence of combined eplerenone, aflibercept and nepafenac therapy on central serous chorioretinopathy. [PDF]

Int J Ophthalmol
Ewais WA, Samy Ali L, Aboalazayem F.
europepmc   +1 more source

Recent advances in mineralocorticoid receptor antagonists for heart failure with preserved ejection fraction: focus on finerenone in the era of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists. [PDF]

Front Pharmacol
Wang TY, Zhang L, Wang HY, Jiang FF.
europepmc   +1 more source